Consider Switching Some VTE Patients to a Low-Dose Direct Oral Anticoagulant

June 2017

More patients will use LOW-dose direct oral anticoagulants (DOACs) long-term to prevent recurrent venous thromboembolism (VTE).

We're used to giving warfarin or a DOAC (Eliquis, etc) for 3 months for patients who have a VTE due to a short-term risk such as surgery or minor trauma.

And we know to use long-term anticoagulation to prevent a VTE recurrence for most patients at high risk...such as those with active cancer or a clotting disorder.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote